Postpartum timing of teriparatide initiation and BMD response in pregnancy- and lactation-associated osteoporosis: an observational study
Authors' conclusion
These data highlight the complexity of assessing treatment response in the context of postpartum bone physiology and can inform treatment response expectations for women with PLO.
Study context
- Population
- Women with pregnancy- and lactation-associated osteoporosis (PLO) treated with teriparatide, PLO Registry
- Participants
- 31 women
- Exposure
- Teriparatide initiated <12 months postpartum vs ≥12 months postpartum
- EarlyRxn = 10
- DelayedRxn = 21reference
- Outcome
- BMD response to teriparatide (% change at LS, TH, FN)
- Follow-up
- 12M
Methodological detailsregistry-based
- Registry-based
Main finding
As reported in the abstract
LS BMD increase
EarlyRx
+ 21
SD 12 · %
DelayedRx
+ 8
SD 5 · %
Observational data: associations, not effects.
Further findings
| Outcome | EarlyRx | DelayedRx |
|---|---|---|
| TH BMD increase · 12M | + 9 (SD 6) % | + 4 (SD 4) % |
| FN BMD increase · 12M | + 7 (SD 6) % | + 2 (SD 3) % |
Baseline BMD
- Baseline BMD lower in EarlyRx vs DelayedRx
Original publication
Postpartum timing of teriparatide initiation and BMD response in pregnancy- and lactation-associated osteoporosis: an observational study. Osteoporos Int. Published 11 May 2026. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →